MAPT and Alzheimer disease: Biomarkers specific for AD include decreases in cerebral spinal cord fluid (CSF) and plasma Aβ42 and the Aβ42/Aβ40 ratio and increases in CSF and plasma phospho-Tau (pTau) species.